Charles J. Homcy - Aug 16, 2022 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Director
Signature
/s/ Brian C. Stephenson, Attorney-in-Fact
Stock symbol
BBIO
Transactions as of
Aug 16, 2022
Transactions value $
-$14,260
Form type
4
Date filed
8/18/2022, 06:33 PM
Previous filing
Jun 24, 2022
Next filing
Nov 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Options Exercise +3.76K +0.31% 1.21M Aug 16, 2022 Direct F1
transaction BBIO Common Stock Tax liability -$14.3K -1.29K -0.11% $11.08 1.21M Aug 16, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Restricted Stock Units Options Exercise $0 -3.76K -14.29% $0.00 22.6K Aug 16, 2022 Common Stock 3.76K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,760 shares of Common Stock underlying the Reporting Person's RSUs.
F3 The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.